Palatin Technologies, Inc. PTN
Set alert
5.31 USD +0.31 +6.20%
As of Nov 2, 3:16 PM ET
4.83 Day range 5.31
4.51 52-week range 31.00
- YTD
- -65.47%
- 1 year
- -20.15%
- Open
- 5.12
- Prev close
- 5.00
- Mkt cap
- 9.46M
- Vol
- 28.62K
- Avg vol
- 69.09K
- EPS
- -2.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.83
- High
- 5.31
- Forward P/E
- 0.52
- Beta
- 0.94
- Short ratio
- 4.47
- Inst. own
- 7.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 1.03
- 200-d avg
- 1.51
- 1y target
- 17.00
6M chart
Signals (27)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| RSI: Oversold | Jul 28, 2026 | 3 months ago |
| RSI: Oversold | Jul 24, 2026 | 3 months ago |
| RSI: Oversold | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 2, 2026 | 4 months ago |
| RSI: Oversold | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| RSI: Oversold | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| RSI: Oversold | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 6, 2026 | 6 months ago |
Key statistics
- Market cap
- 22.75M
- Enterprise value
- 11.98M
- Trailing P/E
- 0.00
- Forward P/E
- 0.52
- PEG ratio
- 0.00
- Price / sales
- 5.07
- Price / book
- 0.00
- EPS (TTM)
- -1.98
- Beta
- 0.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.49M
- Revenue growth
- -80.10%
- Free cash flow
- -17.11M
- Total cash
- 9.53M
- Total debt
- 590.34K
- Return on equity
- 0.00%
- Shares outstanding
- 23.46M
- Short % of float
- 6.12%
- 50-day average
- 1.03
- 200-day average
- 1.51
Analyst view
Consensus: buy
Buy
Price target (mean) 17.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -0.42.
Financials — quick view
PTN Revenue — quarterly 300.77K
PTN Net income — quarterly -4.36M
PTN EPS — quarterly -1.33
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -0.42 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | -0.51 | -0.39 | +0.12 | +23.53% |
| Oct 1, 2024 | Jun 1, 2024 | 0.00 | -0.51 | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.66 | -0.53 | +0.13 | +19.70% |
| Feb 14, 2024 | Dec 1, 2023 | -0.43 | -0.56 | -0.13 | -30.23% |
| Nov 14, 2023 | Sep 1, 2023 | -0.75 | -0.48 | +0.27 | +36.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palatin.com
News
- What Palatin Technologies (PTN) Said on Its Q4 Earnings Call
- Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Gold Fields, Harmony Gold Mining, Anglogold Ashanti And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
- Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
- Palatin Techs Q4 EPS $(1.11) Up From $(2.73) YoY, Sales $300.770K
- Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
- Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on PTN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE VEER ROBERT K JR | Director | Stock Award(Grant) | Jul 14, 2024 | 38,065 |
| DUNTON ALAN WILLIAM | Director | Stock Award(Grant) | Jul 14, 2024 | 42,294 |
| HULL JOSEPH STANLEY | Director | Stock Award(Grant) | Jul 14, 2024 | 42,272 |
| MANNING ANTHONY M | Director | Stock Award(Grant) | Jul 14, 2024 | 36,080 |
| MORRIS ARLENE M. | Director | Stock Award(Grant) | Jul 14, 2024 | 41,580 |
| PRENDERGAST JOHN K. A. PH.D. | Director | Stock Award(Grant) | Jul 14, 2024 | 63,310 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.04% | 593,824 | 576.01K | Sep 29, 2024 |
| LPL Financial LLC | 0.95% | 186,396 | 180.80K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.93% | 181,706 | 176.25K | Sep 29, 2024 |
| Blackrock Inc. | 0.81% | 158,246 | 153.50K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.77% | 150,143 | 145.64K | Sep 29, 2024 |
| HB Wealth Management, LLC | 0.30% | 59,300 | 57.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.18% | 426,848 | 414.04K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.79% | 154,449 | 149.81K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 109,669 | 106.38K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 36,025 | 34.94K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 32,071 | 31.11K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 25,844 | 25.07K | Oct 30, 2024 |